HKD 87.8
(1.8%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 4.66 Billion CNY | 58.16% |
2022 | 2.94 Billion CNY | 93.24% |
2021 | 1.52 Billion CNY | 275.99% |
2020 | 405.73 Million CNY | -72.16% |
2019 | 1.45 Billion CNY | 790.6% |
2018 | 163.62 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 5.31 Billion CNY | 0.0% |
2023 FY | 4.66 Billion CNY | 58.16% |
2023 Q2 | 4.09 Billion CNY | 0.0% |
2023 Q4 | 4.66 Billion CNY | 0.0% |
2022 FY | 2.94 Billion CNY | 93.24% |
2022 Q2 | 2.62 Billion CNY | 0.0% |
2022 Q4 | 3.13 Billion CNY | 0.0% |
2021 FY | 1.52 Billion CNY | 275.99% |
2021 Q2 | 782.2 Million CNY | 0.0% |
2021 Q4 | 1.78 Billion CNY | 0.0% |
2020 Q4 | 417.68 Million CNY | 0.0% |
2020 FY | 405.73 Million CNY | -72.16% |
2020 Q2 | 490.14 Million CNY | 0.0% |
2019 Q4 | 1.56 Billion CNY | 0.0% |
2019 FY | 1.45 Billion CNY | 790.6% |
2019 Q2 | 140.95 Million HKD | 0.0% |
2018 FY | 163.62 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -2950.893% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 33.944% |